

TENDER NO. BMSIC/DRUGS/18-04

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name <u>TERRACE PHARMACEUTICALS PVT. LTD.</u> Total Number of Pages Submitted in bid documents <u>1</u> TO <u>120</u>						
Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(a)	Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft drawn in Favor of “Managing Director, Bihar Medical Services and Infrastructure Corporation Limited” payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	yes	"02"	yes	
2	3.(b)	Bidder are required to submit Earnest Money Deposit in the form of Demand Draft / Bank Guarantee drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/-(Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	yes	"68"	yes	
3	3.(c)	Documentary evidence of the constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	yes	"13"	yes	
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	yes	—	yes	
5	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	yes	"04"	yes	
6	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	yes	"73"&"71"&"69"	yes	

Archana Singh
12/11/2018

7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	yes	"63"- "61"	yes	
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	yes	"06"	yes	
9	3.(q)	Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).	yes	"67"- "65"	yes	

Archana Singh
14/7/2018

13/

TENDER NO. BMSIC/DRUGS/18-04

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name: Terrace Pharmaceuticals Pvt. Ltd.									Total Number of Pages Submitted in bid documents: 120		
Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks					
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	–	–	–	Not given					
2	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	Yes	5	Yes	In Resolution of Board (Pg. no. 4) Mr. Rajesh Chopra has been authorised by the firm how ever on pg. no. 5 authorised to Mr. Amarjeet Singh is given by Rovin chopra					
3		Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.	Yes	60	Yes	–					
4		Approved product list as per the license issued for quoted drugs for minimum three years.	Yes	34-57	Yes	–					
5		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	34-44	Yes	–					
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	No		No	–					

Sanjay Kumar Pandey
14/02/18

7	3.(f)	Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	14--33	No	NIT Sr.No.-, 93,94, 126 Market standing certificate is valid to 28-05-2016 NIT Sr.No.- 100, Market standing certificate is valid to 08-05-2015 NIT Sr.No.- 213 Market standing certificate is valid to 24-05-2016
8		If permission in Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI has been obtained, then the 3 years manufacturing/ Import & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	No	-	No	-
9		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCGI (I) shall be required for all new regulated products to this effect.	No	-	No	-
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	No	-	No	-
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	No	-	No	-
11	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	No	-	No	-

Sanjay Kumar Pansari
14/07/18

12	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	14-33		NIT Sr.No.- 93,94, 126 Market standing certificate is valid to 28-05-2016 NIT Sr.No.- 100, Market standing certificate is valid to 08-05-2015 NIT Sr.No.- 213 Market standing certificate is valid to 24-05-2016
13	3.(i)	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. Self-attested copies are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	Yes	7	Yes	—
14	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. Self-attested copies are to be submitted.	Yes	1	Yes	—
15	3.(k)	Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	Yes	3	Yes	Submitted document not self attested given.
16	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	Yes	76-77	—	Whether Blacklisted or not Nonblacklisted affidavit given but NIT sr. no. 90,213 & 214 drug name not listed in submitted documents as per Annexure-II.

Sanjay Parmar
12/02/18

17	3.(o)	List of item quoted in prescribed format as per Annexure-III duly signed.	Yes	78-80	Yes	—
18	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	Yes	75	Yes	—
19	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	No	—	No	Not given
20	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	4	Yes	In Resolution of Board (Pg. no. 4) Mr. Rajesh Chopra has been authorised by the firm how ever on pg. no. 5 authorised to Mr. Amarjeet Singh is given by Rovin chopra
21	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	No	—	No	—
22	Corrigendum point	A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.	Yes	81	Yes	—

Sanjay Kumar Pandey
14/08/18

TENDER NO. BMSIC/DRUGS/18-04														
Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids														
Company name: Terrace Pharmaceuticals Pvt. Ltd Total number of pages submitted in bid documents: 120														
Sheet to be used for verification of product approval and market standing														
Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug	
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name		
1	24	Azithromycin Tablets IP	(i) Azithromycin 250 mg Tablets IP (ii) AZIPIL 250	250 mg	IP/250 mg	10 x 10	10's Blister	Tablet	Tablet	(i) 20-10-2012 (pg. no. 37) (ii) 20.10.2012	17-01-2022 (pg. no. 44)	(i) Generic (ii) Brand	*1 (pg. no. 23)	
2	25	Azithromycin Tablets IP	(i) Azithromycin 500 mg Tablets IP (ii) AZIPIL 500	500 mg	IP/500 mg	10 x 10	10's Blister	Tablet	Tablet	(i) 20-10-2012 (pg.no. 57) (ii) 26.09.2012 Pg. no. 43	17-01-2022 (pg. no. 43)	(i) Brand (ii) Generic	*2 (pg. no. 23)	
3	44	Cefixime Tablet IP	(i) Cefixime Tablet IP (ii) Cefixime Dispersible tablete IP 50 mg	50 mg	IP/50 mg	10 x 10	—	Dispersible Tablet	Dispersible Tablet	15-06-2013 (pg. no. 56) 30.03.2012 (pg. no. 42)	17-01-2022 (pg. no. 42)	Generic	Yes * 3 (Pg. 21)	
4	47	Cefoperazone Injection IP	Cefoperazone Injection IP	1 gm	IP/1000 mg	Vial	1g/vial	Powder for Injection	Injection	27-07-2012 (pg. no. 40)	17-01-2022 (pg. no. 40)	Generic	Not given	
5	85	Fluoxetine Hydrochloride Capsule IP	Fluoxetine Hydrochloride Capsule IP CADDY-20	20 mg	IP/20 mg	10x10's	10's Blister	Capsules	Capsules	20-10-2012 (pg. no. 55)	17-01-2017 (pg. no. 55)	Brand	Yes (Pg. 20) *4	
6	87	Febuxostat Tablet	Febuxostat Tablet	40mg	IP 40mg	10x10	—	Tablet	Tablet	24-01-2014 (pg. no. 34)	Not Mentioned	Generic	Given upto 28-05-2016 (Pg. 32)	
7	90	Fusidic Acid Cream IP	Fusidic Acid Cream IP	2% w/w	IP/2% w/w	30 gm Tube	Not Mentioned	Cream	Cream	30-03-2012 (pg. no. 42)	17-01-2022 (pg. no. 42)	Generic	Yes (Pg. 19) *5	
8	93	Glyceryl Trinitrate Tablet	Glyceryl Trinitrate 2.6 mg Tablet SR	2.6 mg	IP/2.6 mg	10 x 10	Not Mentioned	Tablet	Tablet	09-11-2015 (pg. no. 54)	17-01-2017 (pg. no. 54)	Generic	*6	
9	94	Glyceryl Trinitrate Tablet	Glyceryl Trinitrate 6.4 mg Tablet SR	6.4 mg	IP/6.4 mg	10 x 10	Not Mentioned	Tablet	Tablet	09-11-2015 (pg. no. 54)	17-01-2017 (pg. no. 54)	Generic	*7	

Sanjay Janner Partner
17/08/18

10	100	Haloperidol Tablet IP	(i) Haloperidol Tablet IP HAPIWIN-5 (ii) Haloperidol Tablet IP	5mg	IP/5 mg	10 x 10	10's Blister	Tablet	Tablet	Tablet	20-10-2012 (pg. no. 53)	17-01-2022 (pg. no. 41)	(i) Brand (ii) Generic	*8
11	117	Lactulose solution	(i) Lactulose solution (ii) lactulose syrup	10gm/15ml	(i) USP/10 gm (ii) BP/10 gm	100 ml bottle	Not Mentioned	suspension	(i) solution (ii) Syrup	(i) 15-06-2013 (pg. no. 41) (ii) 27.07.2012 Pg. no. 56	(i) 17-01-2022 (ii) 17.01.2017	Generic	*9	
12	118	Levofloxacin Tablet IP	(i) Levofloxacin Tablet IP 250 mg (ii) Lfox 250mg	250 mg	IP/250 mg	10 x 10	10' Blister	Tablet	Tablet	(i) 19-03-2012 (ii) 20.10.2012	17-01-2022 17.01.2017	Generic Brand	*10 (Pg. 23, 33)	
13	119	Levofloxacin Tablet IP	(i) Levofloxacin Tablet IP 500 mg (ii) Lfox 5000mg	500 mg	IP/500 mg	10 x 10	10' Blister	Tablet	Tablet	17-03-2012 20.10.2012	17-01-2022 17.01.2017	Generic Brand	*11 (Pg. 25)	
14	126	Linezolid IP	Linezolid Tablet IP	600mg	IP/600 mg	10 x 10	10 x 10	Tablet	Tablet	21-12-2013 Pg. no. 50	Not Mentioned	Generic	*12	
15	166	Ofloxacin Tablet IP	(i) Ofloxacin Tablet IP 200 mg (ii) OLACIN Tablets	200mg	IP 200 mg	10 x 10	10' Blister	Tablet	Tablet	(i) 30-03-2012 (pg. no. 42) (ii) 20.10.2012 (pg. no. 50)	17-01-2022 17.01.2017	Generic Brand	*13	
16	179	Piperacillin Sodium + Tazobactam	(i) Piperacillin Sodium + Tazobactam Inj. IP (ii) Piperacillin Sodium + Tazobactam Inj. IP	4000 mg + 500 mg (4.5gm)	(i) USP/4gm +500 mg (ii) IP 4 gm +500 mg	Vial	4.5 gm/vial	Powder for Injection	Powder for Injection	(i) 13.02.2014 (pg. no. 48) (ii) 19-03-2012 (pg. no. 37)	17.01.2017 17-01-2022	Generic	*14	
17	180	Prednisolone Tablets IP	Prednisolone Tablets IP PREDEN-20	20 mg	IP/20 mg	10 x 10	10' Blister	Tablets	Tablets	20-10-2012	17-01-2017 (pg. no. 47)	Brand	*15	
18	208	Tranexamic Acid Tablet IP	Tranexamic Acid Tablet BP TREXAMIC	500 mg	BP/500 mg	10 x 10	10' Blister	Tablets	Tablets	20-10-2012	17-01-2017 (pg. no. 47)	Brand	*16	
19	213	Thyroxine sodium Tablet IP	Thyroxine sodium Tablet IP 50 mcg	50mcg	IP/50 mcg	100 Tablets in Bottle	(i) 10' Blister (ii) 10s alu - alu (iii) 10s strips	Tablet	Tablets	(i) 20-10-2012 (pg. no. 36) 07.02.2013 (pg. no. 45)	(i) 17-01-2022 (ii) 17.01.2017 (pg. no. 45)	Generic	*17	
20	214	Thyroxine sodium Tablet IP	Thyroxine sodium Tablet IP 100 mcg	100mcg	IP/100 mcg	100 Tablets in Bottle	Not Mentioned	Tablet	Tablet	17-03-2012	17-01-2022	Generic	Yes (pg. 14)	

Sanjay Kumar Pandey
14/10/2018

Note *1- NIT sr. no.-24 Market standing Certificate given in Brand name Azipro 250 Tablets up to 08.06.2018 (Pg. no.-23)
Note *2- NIT sr. no.-25 Market standing Certificate given in Brand name Azipro 500 Tablets up to 08.06.2018 (Pg. no.-23) (Pg. no.-23-33)
Note *3- NIT sr. no.-44 Market standing Certificate given in Brand name Asfin 50 DT Tablets up to 08.06.2018 (Pg. no.-21)
Note *4- NIT sr. no.-85 Market standing Certificate given in Brand name CADDY -20 Tablets (Pg. no.-20) up to 08.06.018
Note *5- NIT sr. no.-44 Market standing Certificate given in Brand name FUDIL (Pg. no.-19) up to 08.06.18
Note *6- NIT sr. no.-94 Market standing Certificate given in Brand name (Pg. no.-27) and given upto 28-05-2016.
Note *7- NIT sr. no.-94 Market standing Certificate given in Brand name (Pg. no.-27) and given upto 28-05-2016.
Note *8- NIT sr. no.-100 Market standing Certificate given in Brand name (Pg. no.-29).
Note *9- NIT sr. no.-117 Market standing Certificate given in Brand name Lactulose solution (Loozsun solution) (Pg. no.-18) up to 08.06.2018
Note *10- NIT sr. no.- 118 Market standing Certificate given in Brand name (Pg. no.-23). upt o 08.06.2018 - Leflox 250mg
Note * 11- NIT sr. no.-119 Market standing Certificate given in Brand name (Pg. no.-19). upt o 08.06.2018 - Leflox 500mg
Note *12- NIT sr. no.-126 Market standing Certificate given upto 28-05-2016. (pg. no 32)
Note *13- NIT sr. no.-166 Market standing Certificate given in Brand Name Flomin 200mg upto 8-06-2018. (pg. no 16)
Note *14- NIT sr. no. 179 Market standing Certificate given upto Brand Name Pipalin 4.5 Injection 08-06-2018 . (pg. no 14)
Note *15- NIT sr. no. 180 Market standing Certificate given upto Brand Name PRE DEN 10 TABLETS 08-06-2018 . (pg. no 19)
Note *16- NIT sr. no. 208 Market standing Certificate given upto Brand Name Trexmaie Tablets In BP 08-06-2018 . (pg. no 15)
Note *17- NIT sr. no.- 213 Market standing Certificate given in Brand name Thypile 50 mg (Pg. no.-22) and given upto 24-05-2016.
Note *18- NIT sr. no. 214 Market standing Certificate given upto Brand Name Thypil - 100 Tablets 08-06-2018 . (pg. no 14)

Sanjay Kumar
12/08/18

TENDER NO. BMSIC/DRUGS/18-04												
Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids												
Company name: Terrace Pharmaceuticals Pvt. Ltd. Total number of pages submitted in bid documents: 120												
Sheet for verification of licence details												
Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)			
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To	From	To
1	24	Azithromycin Tablets IP	28	BNZ/07/22	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
2	25	Azithromycin Tablets IP	28	BNZ/07/22	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
3	44	Cefixime Tablet IP	28	BNZ/07/22	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
4	47	Cefoperazone Injection IP	28	BNZ/07/22	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
5	85	Fluoxetine Hydrochloride Capsule IP	25	NNZ/07/21	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
6	87	Febuxostat Tablet	25	NNZ/07/21	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
7	90	Fusidic Acid Cream IP	25	NNZ/07/21	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		
8	93	Glyceryl Trinitrate Tablet	25	NNZ/07/21	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020		

Sanjay Kumar Pandey
14/08/18

9	94	Glyceryl Trinitrate Tablet	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
10	100	Haloperidol Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
11	117	Lactulose solution	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
12	118	Levofloxacin Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
13	119	Levofloxacin Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
14	126	Linezolid IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
15	166	Ofloxacin Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
16	179	Piperacillin Sodium + Tazobactam	28	BNZ/07/22	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
17	180	Prednisolone Tablets IP	28	BNZ/07/22	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
18	208	Tranexamic Acid Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
19	213	Thyroxine sodium Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020
20	214	Thyroxine sodium Tablet IP	25	NNZ/07/21	-	-	-	18-01-2007	17-01-2022	29-01-2018	28-01-2020

Sanjay Kumar Pandey
14/07/18